DSM expands industrial biocatalysis platform with c-LEcta agreement
Advertisement
DSM Pharmaceutical Products announced a license agreement with c-LEcta GmbH for proprietary screening technology. The agreement grants DSM rights to c-LEcta’s proprietary alcohol dehydrogenases for enzyme screening programs and development of sustainable manufacturing routes for manufacturing of pharmaceutical active ingredients and intermediates.
Dr. Oliver May, Business Manager for DSM comments: “This agreement further broadens our alcohol dehydrogenase platform which we setup for rapid screening programs for our customers and the development of cost efficient production of a large spectrum of chiral secondary alcohols.”